Checklist for Identifying PPI Deprescribing Candidates

Did you know that up to 80% of long-term PPI use might be unnecessary? Many patients stay on proton pump inhibitors (PPIs) longer than needed, increasing their risk of side effects like fractures, kidney disease, and nutrient deficiencies. Deprescribing, or safely reducing or stopping PPIs, helps minimize these risks while ensuring patient safety.

Here’s a quick breakdown of how to identify candidates for PPI deprescribing:

• Review therapy duration: Most GERD and ulcer treatments only require 4–12 weeks of PPI use.
• Check original diagnosis: Confirm if the PPI was started for GERD, ulcers, or other valid reasons.
• Assess symptoms: If the patient has been symptom-free for 3+ months, they may be ready to taper off.
• Exclude high-risk patients: Some conditions, like Barrett’s esophagus or severe esophagitis, require continued PPI use.
• Evaluate risk factors: Consider age, comorbidities, and medication interactions before deprescribing.
• Patient involvement: Ensure they understand the process, can track symptoms, and have access to follow-up care.

Using the PPI Deprescribing Algorithm – When to Reduce or Stop PPIs and How?

Step 1: Basic Patient Screening

The first step in evaluating PPI (proton pump inhibitor) use is to review the therapy duration, the original reason for starting treatment, and the patient’s current symptoms.

How Long Has the Patient Been on PPIs

For conditions like GERD, patients typically complete a 4–8 week course of PPIs if their symptoms are under control. For peptic ulcer disease, treatment can range from 2–12 weeks depending on the severity. It’s important not to stop PPI therapy before meeting these minimum treatment durations.

Make sure to document all PPI use, including both prescription and over-the-counter options like Prilosec, Nexium, or Prevacid.

Why Was PPI Therapy Started

Take a close look at the original diagnosis that led to PPI therapy. Common reasons include GERD, peptic ulcer disease, Barrett’s esophagus, NSAID protection, and dyspepsia. This review helps confirm whether there’s still a valid need for the medication.

Sometimes, the original reason for starting PPIs isn’t well-documented. For instance, many patients are started on PPIs during hospital stays to prevent stress ulcers but continue taking them unnecessarily after discharge. If there’s no clear ongoing medical need, the patient might be a good candidate for deprescribing.

What Are the Patient’s Current Symptoms

Assess whether symptoms like heartburn, acid reflux, regurgitation, chest pain, or dyspepsia have resolved. If the patient has been symptom-free for several weeks or months, they may be ready to taper off PPIs.

Patients who have gone three months or longer without symptoms – especially those with mild GERD or occasional heartburn – are often strong candidates for deprescribing. However, if symptoms persist, continued therapy or further investigation is likely needed before making changes.

It’s also essential to address any concerns the patient may have about stopping PPIs. Anxiety about symptom recurrence can impact the success of deprescribing efforts.

In 2020, medical residents at the University at Buffalo introduced a checklist to review PPI prescriptions. Over six months, this approach reduced inappropriate long-term PPI use by 30%.

High-Risk Patients to Exclude

At this stage, it’s critical to identify and exclude patients who aren’t suitable for deprescribing. These include individuals with conditions like Barrett’s esophagus, severe erosive esophagitis (LA grade C or D), esophageal ulcers, peptic strictures, or those at a high risk of upper gastrointestinal bleeding.

Once the basic screening is complete, move on to Step 2, where the patient’s medical history will be reviewed in greater detail.

Step 2: Review Medical History

Taking a close look at the patient’s medical history is a key step in determining whether deprescribing is appropriate. This helps avoid complications and ensures the patient’s safety.

Conditions That Require Continued PPI Use

Some medical conditions absolutely require ongoing PPI therapy. These include Barrett’s esophagus, severe erosive esophagitis (LA grade C or D), esophageal ulcers, peptic strictures, and a history of upper gastrointestinal bleeding. Additionally, patients with hypersecretory conditions, such as Zollinger-Ellison syndrome, need long-term PPI treatment.

For patients with these conditions, stopping PPIs without specialist oversight is not recommended. The risks – like bleeding, stricture formation, or even cancer progression – far outweigh any potential advantages of discontinuing the medication.

Past Test Results and Findings

Recent diagnostic tests and endoscopy results are critical for making informed deprescribing decisions. If the tests show healed mild-to-moderate esophagitis or resolved peptic ulcer disease, deprescribing may be considered appropriate. On the other hand, evidence of persistent or severe disease indicates the need to continue therapy.

When recent test results are unavailable or outdated, it’s worth considering repeat testing before deciding on deprescribing. Up-to-date findings are essential for accurate decision-making.

Need for Stomach Protection

Certain medications can increase the risk of gastrointestinal bleeding, making continued PPI use necessary. Patients taking NSAIDs, aspirin, anticoagulants, or antiplatelet agents – particularly those over 60, with a history of GI bleeding, or using corticosteroids – often need ongoing PPIs for protection.

Evaluate the combination of risk factors carefully. For example, a patient with a history of a bleeding gastric ulcer who is on daily aspirin would generally continue PPI therapy. In such cases, the protective benefits of PPIs outweigh the risks of long-term use.

Other factors that can heighten bleeding risk include severe comorbidities, the use of multiple antithrombotic medications, or combining corticosteroids with NSAIDs. These risk factors should be documented clearly, as they may change over time and influence future deprescribing decisions.

If no valid indication for continued use is found and the patient shows no symptoms, deprescribing is generally recommended, with careful monitoring for any return of symptoms.

Studies reveal that personalized deprescribing plans, developed after a thorough review of medical history, lead to successful PPI discontinuation in 75–82% of eligible patients. This highlights how critical it is to carefully select patients based on their medical history.

For healthcare providers looking to expand their knowledge of acid reflux and related conditions, resources like the Reflux Online Summit offer expert-led sessions on diagnostics, lifestyle adjustments, and treatment options from a range of professionals, including doctors and nutritionists.

Step 3: Check Risk Factors

Taking a close look at patient-specific risk factors is essential for safely and effectively reducing or stopping PPIs. These factors help predict potential complications and guide how you approach the deprescribing process. Building on the patient’s medical history, this step focuses on identifying risks that could influence the overall safety and success of discontinuing PPIs.

Age and Other Health Conditions

Older adults and those with multiple health issues are at greater risk when discontinuing PPIs. For instance, patients over 65 are more vulnerable due to age-related metabolic changes and increased sensitivity to medications. Frailty adds another layer of complexity – consider an 80-year-old with a history of falls and multiple medications. In such cases, a slower taper and more frequent follow-ups are often necessary. Additional conditions like chronic kidney disease, osteoporosis, or a history of gastrointestinal bleeding require extra care. Functional status and cognitive abilities also play a role, as even mild cognitive impairment can make it harder for patients to monitor symptoms or manage a detailed tapering plan.

Previous Attempts to Stop PPIs

Understanding past efforts to stop PPIs provides valuable insight. Document whether previous attempts were abrupt or gradual and note any recurring symptoms such as rebound acid, heartburn, indigestion, or regurgitation. Abrupt discontinuation often leads to significant symptom recurrence, which can make patients hesitant to try again. A gradual taper, supported by pharmacist-led interventions or a multidisciplinary team, tends to yield better outcomes. For example, one study found that 81.6% of older patients in long-term care successfully discontinued PPIs using a personalized approach. For those with severe symptom recurrence, strategies like on-demand therapy, slower tapering, and thorough patient education, combined with close symptom tracking, are especially helpful.

Drug Interactions

Review the patient’s complete medication list for potential interactions with PPIs, especially with drugs like clopidogrel, certain antifungals, and antiretrovirals. For instance, deprescribing PPIs in patients taking clopidogrel could increase the risk of gastrointestinal bleeding, which might require alternative protective measures. Additionally, consider how other medications depend on stomach acidity – some need acid suppression for proper absorption, while others require an acidic environment.

Using standardized checklists or algorithms during medication reviews can ensure a thorough assessment of these risks. Integrating these tools into electronic health records and collaborating with the entire healthcare team can further improve the safety and consistency of the deprescribing process.

Step 4: Patient Willingness and Understanding

Getting patients involved is key to successfully reducing or stopping PPI use. This step focuses on ensuring patients are well-informed, capable of monitoring their symptoms, and supported throughout the process.

Does the Patient Understand the Process?

Educating patients is the foundation of successful deprescribing. They need to understand what the process involves, including the potential for rebound acid hypersecretion. This is a temporary increase in stomach acid that can lead to symptoms like heartburn or indigestion. Healthcare providers should explain why deprescribing is being recommended, the expected timeline, and the potential benefits and risks. For instance, long-term PPI use has been linked to a higher risk of fractures, especially in adults over 50.

Using tools like direct questions or shared decision-making techniques can help confirm patient understanding. For example, asking them to explain the process in their own words or identify when they should seek help ensures clarity. Once understanding is established, the next step is to ensure they can effectively monitor their progress.

Can the Patient Track Symptoms?

Symptom tracking is a critical part of safe deprescribing. Patients need to be both willing and able to monitor changes in symptoms such as heartburn, regurgitation, or abdominal pain – issues that might require medical attention. Providers should offer simple and accessible tracking methods tailored to the patient’s needs. Options might include a paper diary, a mobile app, or regular check-ins via phone calls. Clear instructions about which symptoms to monitor, how to record them, and when to contact a healthcare provider are essential.

For patients who may have cognitive challenges or struggle with technology, involving family members or caregivers can ensure accurate symptom reporting. This collaborative approach supports consistent and reliable monitoring.

Is Follow-Up Care Available?

Strong follow-up care is the final piece of patient engagement. Patients need to feel confident that support is available if they encounter complications or recurring symptoms. This often includes scheduled follow-ups – commonly at 4 and 12 weeks – to evaluate symptom control and address concerns. Research shows that consistent follow-up improves outcomes and helps identify patients who may need to restart therapy.

Patients should also know how to access care between visits, including when to seek immediate medical attention. In settings with a multidisciplinary team, pharmacists or nurse advisers can provide extra support, especially in managing rebound symptoms. Providers should also consider practical barriers like insurance, transportation, or scheduling issues. Telehealth options may be a helpful alternative for some patients.

The Reflux Online Summit (https://refluxsummit.com) offers a wealth of educational resources for both patients and providers, including expert-led sessions on managing reflux and strategies for effective deprescribing.

Finally, documenting the patient’s understanding, willingness, and support systems in their medical record ensures continuity of care. Collaborative care models that involve patients in setting goals and creating action plans have shown success rates of over 75% in deprescribing interventions. This coordinated effort strengthens the overall deprescribing strategy.

sbb-itb-8cfe404

Step 5: Make the Decision and Create a Plan

Once you’ve assessed the patient’s readiness, the next step is to decide on a deprescribing plan. This involves selecting the right method, scheduling follow-ups, and documenting every detail to ensure patient safety and continuity of care.

Choose a Deprescribing Method

The choice of method should align with the patient’s medical history and individual needs. Research shows that 14–64% of patients can stop using PPIs without their symptoms worsening, with non-GERD patients having higher success rates than those with GERD.

• Abrupt Discontinuation: This method involves stopping PPIs immediately. While it’s suitable for patients who started PPIs for unclear reasons or mild symptoms that have resolved, it carries a 67% symptom recurrence rate in patients with erosive esophagitis.
• Gradual Tapering: By slowly reducing the dosage over weeks, this approach helps prevent rebound symptoms, making it a better option for GERD patients or those with milder conditions. It’s often more effective than abrupt cessation for patients with a documented GERD history.
• Step-down to H2-Receptor Antagonists (H2RAs): This involves tapering or stopping the PPI and introducing an H2RA at an approved dose. Studies suggest that adding a rescue H2 blocker can lower the risk of restarting PPIs by about 80%. However, it may be less effective for severe GERD cases.
• On-demand Therapy: Patients take medication only when symptoms appear, reducing PPI use by about two-thirds. While this approach cuts pill usage by approximately four pills per week compared to continuous therapy, it may result in less effective symptom control and lower patient satisfaction.

These methods form the foundation for monitoring and follow-up practices.

Set Up Monitoring and Follow-Up

A well-structured follow-up schedule is critical for identifying and managing symptom recurrence early. Regular check-ins should evaluate the patient’s tolerance to the chosen deprescribing method and track any changes in symptoms. For patients on on-demand therapy, monitoring should also include tracking pill usage, which can decrease by about 3.79 pills per week compared to continuous use. Symptom surveys are a helpful tool for assessing outcomes and gauging patient satisfaction throughout the process.

Collaboration among healthcare professionals is key. Involving pharmacists or nurse practitioners can improve the management of rebound symptoms and medication adjustments. Resources like the Reflux Online Summit (https://refluxsummit.com) provide expert guidance on managing reflux conditions and deprescribing strategies, which can be valuable for healthcare teams.

It’s also essential to define clear criteria for restarting PPI therapy. For patients experiencing recurrent symptoms, switching to on-demand therapy may be a better alternative than complete cessation. Patients should be informed about specific symptom thresholds that would necessitate restarting PPIs, especially since two-thirds of patients who abruptly stop PPIs experience symptom recurrence.

Document Everything Properly

Thorough documentation is essential for ensuring safe and effective care. The deprescribing plan should include the original indication for PPI use, the chosen method, and the follow-up schedule. Studies show that 40–65% of hospitalized patients and 40–55% of primary care patients lack documentation of an ongoing need for PPI therapy, highlighting the importance of recording this information.

Documentation should also confirm that the patient has completed at least four weeks of PPI treatment for heartburn or mild to moderate GERD and that symptoms have resolved. This ensures compliance with guidelines and safeguards patient safety.

Key elements to document include:

• The original reason for PPI use and treatment duration.
• The selected deprescribing method and its rationale.
• The follow-up schedule and criteria for restarting PPI therapy.
• Results of any diagnostic tests, such as endoscopic findings or GERD severity classifications like the Los Angeles scale.
• Patient preferences and their understanding of the deprescribing process.

If the plan involves H2RA therapy, record the prescribed H2RA and its dosage details. This level of detail supports seamless transitions and ensures that other healthcare providers can understand the reasoning behind treatment decisions.

Finally, establish and document clear thresholds for restarting PPI therapy. This ensures that all members of the healthcare team are aligned and prepared to respond appropriately to the patient’s needs.

Special Cases That Need Extra Attention

Certain patient groups require a more tailored approach when it comes to deprescribing PPIs. Their unique circumstances often demand strategies that go beyond the usual screening steps, ensuring safety and effectiveness.

Patients Recently Discharged from the Hospital

Hospital discharge is a critical moment where unnecessary PPI use often persists. Many patients leave the hospital still taking PPIs, even though they no longer have a clear medical need for them. This usually happens when PPIs are started during a hospital stay – for example, to prevent stress ulcers in critically ill patients – but aren’t reassessed once the patient stabilizes.

To address this, start by reviewing why the PPI was prescribed in the first place. Was it due to critical illness, mechanical ventilation, or anticoagulation needs? If those risk factors – like coagulopathy or ongoing critical illness – are no longer present, deprescribing should be considered. The first follow-up appointment after discharge is an ideal time to reassess the necessity of the PPI. For patients who were started on PPIs without a clear reason, deprescribing can begin with careful monitoring for rebound symptoms.

Older Patients with Multiple Health Issues

Older adults often face additional challenges when discontinuing medications. Their complex medical conditions, potential cognitive issues, and higher risk of side effects mean that deprescribing requires a slower, more cautious approach. Adjusting one medication at a time and using gradual tapers helps their bodies adapt more easily.

Caregivers play a crucial role here, particularly for those with mild cognitive impairment. They can assist with tracking symptoms and ensuring adherence to the deprescribing plan. Before making any changes, conduct a thorough medication review to identify possible drug interactions, such as those involving H2-receptor antagonists. Reducing the overall number of medications not only simplifies management but can also improve health outcomes and lower the risk of hospitalizations.

Patients on PPIs for Unclear Reasons

In many cases, primary care patients continue using PPIs without a documented reason. When the original indication for the medication is unclear, deprescribing is often the best course of action. To determine if PPIs are still necessary, consider whether the patient has undergone an endoscopy, been hospitalized for a bleeding ulcer, or received PPIs for gastroprotection. A focused conversation with the patient can also help clarify why the medication was started.

If deprescribing is appropriate, ensure the process is accompanied by clear documentation and regular symptom monitoring. Educate patients about the possibility of rebound symptoms and how to manage them. Once the decision is made, document the lack of indication, the reasons for stopping the medication, and the follow-up plan. Annual reviews provide a good opportunity to reassess whether PPIs are still needed.

Conclusion: Making PPI Deprescribing Work in Practice

Reducing unnecessary PPI use starts with a careful, evidence-based approach to identifying patients who are good candidates for deprescribing. By following the step-by-step checklist detailed earlier, healthcare providers can make these decisions with confidence while prioritizing patient safety.

Structured deprescribing protocols have shown promising results. For example, they can cut down inappropriate PPI use by up to 30% and achieve discontinuation rates exceeding 50% in targeted groups. One 2020 pilot study at a major hospital highlighted the effectiveness of such tools, using a deprescribing checklist to significantly reduce inappropriate PPI prescriptions. This approach, which involved reviewing each patient’s need for PPI therapy and conducting regular follow-ups, demonstrated that systematic deprescribing works in real-world settings.

The benefits of deprescribing are clear: it lightens the medication burden, minimizes adverse effects, lowers healthcare costs, and enhances quality of life. These advantages extend beyond individual patients, positively impacting the healthcare system as a whole.

However, implementing deprescribing in practice is not without its challenges. Providers often face hurdles like patients’ fear of symptom recurrence, limited follow-up resources, uncertainty about tapering strategies, and difficulty distinguishing those who genuinely need continued therapy from those who don’t. Here, the checklist approach proves invaluable by offering clear decision points and thorough documentation, which not only boosts provider confidence but also ensures patient safety.

Patient education and engagement are critical to success. When patients understand why deprescribing is being considered and are actively involved in the process, they’re more likely to follow the plan and report symptoms accurately. The checklist also promotes collaboration among healthcare professionals, ensuring consistent communication and comprehensive support for patients across the care team.

This structured approach seamlessly integrates deprescribing into routine care. Expert panels, including family physicians, pharmacists, and gastroenterologists, now recommend using decision-support tools like checklists and algorithms to guide these efforts. They emphasize the importance of tailoring care to each individual and regularly reassessing the need for ongoing PPI therapy.

For providers seeking to expand their knowledge of acid reflux management and deprescribing strategies, resources like the Reflux Online Summit offer expert-led sessions on GERD, LPR, and other digestive conditions. This complements the checklist framework, providing practical tools and insights to enhance PPI optimization efforts.

Resources for Healthcare Providers

Healthcare providers have access to a variety of evidence-based tools to support PPI deprescribing. The Deprescribing Guidelines in the Elderly project is a valuable resource available at www.open-pharmacy-research.ca/research-projects/emerging-services/deprescribing-guidelines. This site includes a clinical practice guideline developed using the GRADE approach, offering structured frameworks to guide clinicians in safely tapering or discontinuing PPIs.

For practical tools, deprescribing.org provides downloadable algorithms and guidelines specifically designed for PPI deprescribing. These step-by-step tools can seamlessly fit into clinical workflows and even electronic health records, making it easier for providers to evaluate PPI use during regular patient visits. Additionally, the New York State Medication Prescribing and Education Program offers detailed flowcharts that visually guide clinicians through the deprescribing process. These resources are further supported by educational programs that help integrate these tools into daily practice.

To expand their knowledge of reflux management, healthcare providers can explore broader educational opportunities. The Reflux Online Summit features expert-led sessions covering diagnostics, lifestyle modifications, and treatment strategies for reflux conditions. This program enriches providers’ understanding of comprehensive reflux care, complementing the deprescribing tools with a broader perspective on patient management.

Together, these resources bridge the gap between clinical guidelines and practical application. They not only help providers navigate safe PPI deprescribing but also enhance their overall approach to managing reflux conditions. By combining evidence-based deprescribing frameworks with educational insights, healthcare providers can confidently make decisions that prioritize both safety and patient well-being.

FAQs

What are the risks and benefits of stopping long-term PPI use?

Deprescribing proton pump inhibitors (PPIs) for long-term users involves weighing potential upsides against possible downsides, a process that healthcare providers should approach with care.

Potential Benefits: Discontinuing PPIs can lower the chances of side effects tied to extended use, such as nutrient deficiencies (like magnesium and vitamin B12), bone fractures, kidney problems, and gut infections. It also helps cut down on unnecessary medications when PPIs are no longer required.

Possible Risks: Some individuals might face rebound acid hypersecretion, where symptoms like heartburn temporarily flare up after stopping PPIs. For those managing conditions like GERD or Barrett’s esophagus, stopping PPIs without proper oversight could result in symptom recurrence or complications.

To determine if deprescribing is right for you, it’s crucial to consult a healthcare provider. They can assess your specific needs and, if appropriate, guide you through a safe tapering plan.

What are the best ways for patients to track symptoms and manage rebound acid hypersecretion when tapering off PPIs?

Patients who are tapering off PPIs should keep a detailed log of their symptoms. Tracking changes in how often symptoms occur or how intense they feel can help uncover patterns or pinpoint triggers that might aggravate the condition. To ease rebound acid hypersecretion, a gradual reduction in dosage is typically advised. Pairing this with dietary changes and stress-reducing techniques can make the process smoother.

Simple steps like staying well-hydrated and steering clear of common irritants – such as caffeine, alcohol, and spicy foods – can also help minimize discomfort during this transition.

For more personalized advice, consider seeking input from healthcare professionals. Educational resources led by experts can offer practical tips and strategies to help you manage acid reflux and related issues effectively.

Which medical conditions require ongoing PPI use, and how should these cases be managed differently?

Certain medical conditions, like severe GERD, Barrett’s esophagus, Zollinger-Ellison syndrome, or a history of gastrointestinal bleeding, often require long-term use of PPIs to control symptoms and prevent serious complications. For individuals with these conditions, stopping PPIs isn’t usually advised, as it could pose significant health risks.

In such cases, the focus should be on close supervision by a healthcare provider to ensure that the treatment remains effective while using the lowest possible dose. Alongside medication, lifestyle adjustments – like adopting a healthier diet and managing weight – can play a supportive role in maintaining digestive health and enhancing the overall effectiveness of PPI therapy.

Related Blog Posts

• GERD vs Acid Reflux: Key Differences Explained
• Acid Reflux Diet vs Medication: Which Works Better?
• Dysphagia and Acid Reflux: Recovery Stories
• Diaphragmatic Breathing for GERD Relief